We recommend the use of metformin, SGLT-2 inhibitors, or GLP-1 receptor agonists as first-line long-term treatment in patients with type 2 diabetes with previous cardiovascular events and without heart failure. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.